All In Biotech

NDA 208772 · Takeda Pharms USA

Alunbrig

Brigatinib · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Feb 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Apr 28, 2017

Approved uses

4

Original approval plus efficacy supplements

Registered trials

34

2 Phase 3, 8 recruiting

FAERS reports

3,655

3,259 serious, 788 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 12, 2026.

ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 )

Mechanism: Brigatinib is a tyrosine kinase inhibitor (TKI) with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays. Brigatinib also inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of...

Therapeutic areas: Oncology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2022 Supplement 13 · Efficacy OrphanLetterLabel
  • May 22, 2020 Supplement 8 · Efficacy · priority review OrphanLabelLetter
  • Dec 21, 2018 Supplement 4 · Efficacy OrphanLabelLetter
  • Apr 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
3 products under this application
  • ALUNBRIG · BRIGATINIB 180MG · TABLET, ORAL · Prescription
  • ALUNBRIG · BRIGATINIB 30MG · TABLET, ORAL · Prescription
  • ALUNBRIG · BRIGATINIB 90MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Brigatinib" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death431
  • non-small cell lung cancer396
  • off label use307
  • diarrhoea255
  • metastases to central nervous system242
  • nausea234
  • lung neoplasm malignant225
  • blood creatine phosphokinase increased220
  • fatigue216
  • product dose omission issue204
  • drug ineffective185
  • neoplasm progression180

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
201757
2018244
2019310
2020374
2021526
2022579
2023486
2024541
2025377
2026160

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alunbrig (Brigatinib)

2024 spending

$41.9M

Beneficiaries

323

2,175 claims

Per beneficiary

$129,681

$564.90 per unit

View as table
YearSpending
2020$15,825,268
2021$19,416,970
2022$27,828,145
2023$33,349,882
2024$41,887,107

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 71 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.